date:Aug 11, 2021
It is spoken that David Javier Iscovich, Mileutis CEO and co-founder, about the regulatory track and launch of the companys lead product.
Imilac and its claims are backed by controlled clinical studies and independently published research on the pathophysiological benefits obCNH treatments in dairy cows, he remarks. Currently antibiotics is still the dominant strategy for treating and preventing mastitis.
There are certain non-antibiotic treatments that aim to help cows reduce the risk of ma